1. Based on your analysis of the benefits and costs of routine donor screening for ALT-GPT to reduce the incidence of post-transfusion non-A, non-B hepatitis in your blood services region, what action would you recommend on this matter?;Forum, International;Vox Sang,1983
2. Surrogate testing for non-A, non-B hepatitis;Anderson, C.C.; Contreras, M.; Barbara, J.A.J.; Mijovic, V.;Lancet,1987
3. Non-A, non-B hepatitis surrogate testing of blood donations;Dow, B.C.; Mitchell, R.; Follett, E.A.C.;Lancet,1987
4. Non-A, non-B hepatitis surrogate testing of blood donations;Lancet; Requests for reprints to: Mr A C Archer, Regional Blood Transfusion Centre, Southmead, Bristol BS1O,1987